Kornimate/medical-research-clean huggingface dataset:
treatment outcomes for functional dyspepsia based on current international guidelines in multi-ethnic asian patients

Conditions: Functional Dyspepsia

Summary: functional dyspepsia (fd) is among the most established and common functional gastrointestinal disorders (fgids). fd is subdivided into two subtypes based on symptoms: epigastric pain syndrome (eps) and postprandial distress syndrome (pds). based on international guidelines (asian consensus and rome consensus), a prokinetic, medication which promotes gut movement (such as itopride) should be the 1st line treatment for the pds sub-type and a proton pump inhibitor, medication which reduces stomach acid production (such as esomeprazole) should be the 1st line treatment for the eps sub-type. however, in the routine practice in malaysia, proton pump inhibitor is still commonly used as 1st line treatment for fd, regardless of subtypes. this may be one of the reasons why fd continues to be inadequately treated locally and causes poor health-related quality of life (qol) in fd patients. the purpose of this study is to compare the clinical symptoms and quality of life improvement in patients with functional dyspepsia (fd) after treatment according to international guidelines versus treatment according to routine practice. adverse effects when managed according to guidelines versus routine practice will also be evaluated.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with functional dyspepsia using rome iv diagnostic criteria: patients on prior dyspepsia treatment can be recruited after washout period of 2 weeks 2. subject who has ability to provide written informed consent and willingness to comply with the requirement of the protocol 3. able to communicate in english, malay or mandarin languages exclusion criteria: 1. patients with known hypersensitivity to itopride and/or proton pump inhibitors or to any of the excipients of the study medication 2. patients with a contraindication to any of the study drugs 3. pregnant / breast feeding women 4. presence of family history of gi malignancy or alarm features suggested malignancy - e.g. unintentional weight loss (≥ 10% of body weight in recent 6 months), gi bleeding 5. patients consuming regular aspirin or nsaids (except low-dose aspirin at a dose of 325 mg/day or less for cardiovascular prophylaxis) 6. history of erosive esophagitis, peptic ulcer disease within 1 year prior to the screening 7. history of gastrointestinal (gi) malignancy, primary esophageal motility disorder, documented upper gi surgery 8. patients with any hepatobiliary or pancreatic diseases 9. patients with severe depression, anxiety, or other psychological disorder 10. patients with any terminal disease 11. presence of irritable bowel syndrome (rome iv criteria) or inflammatory bowel disease (ibd) 12. other conditions determined by the investigator to be inappropriate for this clinical study

Keywords: itopride proton pump inhibitor functional dyspepsia fgid
bell's palsy with a duration of greater than 8 weeks treated with multiwave locked system intervention

Conditions: Laser Treatment Relieve Symptoms of Chronic Bell's Palsy

Summary: objective: to determine whether photobiomodulation therapy by class iv multiwave locked system laser treatment could relieve symptoms in patients with bell's palsy with a duration of greater than 8 weeks. methods and methods: this randomized controlled trial from may 2021 to april 2023. patients were eligible who had bell's palsy with a duration of greater than 8 weeks on out-patient department of otorhinolaryngology in beijing tongren hospital. the photobiomodulation group received class iv multiwave locked system laser treatment for 3 times per weeks, a total of 6 months. the control group received the same multiwave locked system treatment procedure except the laser parameter. the primary outcome measures comprised house-brackmann facial nerve grading system, sunnybrook facial grading system, facial clinimetric evaluation scale. secondary outcome measures comprised electroneurography, electromyography, and the blink reflex.


Eligibility criteria:
inclusion criteria: * patients were eligible for house-brackmann grading system (hb) greater than or equal to grade 3. * patients were adults over 18 years of age and under 60 years of age; * patients were not received medicine before 2 weeks of trial, such as prednisolone. exclusion criteria: * patients were excluded hb grade 6, or greater than 90% denervation on electroneuronography, or no voluntary electromyography activity, or no latency of early (r1) and late (r2, r2') components in blink reflex patients. * patients were excluded serious mental illness or social problems, and neurological disorders. and systemic disease, such as severe diabetes, malignant tumors, and other serious consumptive diseases, planning for pregnancy, in pregnancy or lactation.

Keywords: bell'palsy photobiomodulation rct enog emg
clinical and neurophysiological evolutions through a functional rehabilitation of social communication in asd

Conditions: Autistic Disorder

Summary: this study aims to identify clinical and biological markers which would allow to evaluate precisely the evolution of children with autism spectrum disorders throughout intervention.

200 children with autism spectrum disorders (1-12 years old) will be included in a 2 years follow-up study. both clinical and neurophysiological evaluations (electrophysiological and eye tracking) will be completed at different times of the follow-up. this integrative approach, combining clinical and biological markers, will allow the identification of different developmental trajectories and then a better individuation of treatment in autism spectrum disorders.

Eligibility criteria:
inclusion criteria: * re-education of social communication exclusion criteria: * multi-handicapped associated to asd

Keywords: neurophysiology
short-term versus 6-week prednisone in the treatment of subacute thyroiditis

Conditions: Subacute Thyroiditis

Summary: the goal of this clinical trial is to compare the efficacy and safety of short-term versus 6-week prednisone in the treatment of moderate-to-severe subacute thyroiditis. the main questions it aims to answer are: does the short-term medication regimen reduce glucocorticoid side effects while achieving similar efficacy as the guideline treatment group? patients with moderate-to-severe symptoms were randomly assigned to receive either 30 mg/day prednisone for 1 week, followed by 1 week of nonsteroidal anti-inflammatory drugs, or the conventional 6-week prednisone therapy in the control group.

this is an open-label, randomized, controlled, and multicenter trial. patients with moderate-to-severe symptoms were randomly assigned to receive either 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal or 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week. the primary endpoint was intergroup differences in treatment efficacy at the end of the treatment course. secondary endpoints included between-group differences in post-withdrawal adverse effect parameters and thyroid function at weeks 6, 12, and 24.

Eligibility criteria:
inclusion criteria: * we enrolled adult patients (age 18-70) with subacute thyroiditis (sat) scores ≥3 points. sat was diagnosed on the basis of diagnostic criteria. the severity of sat was scored as follows: fever - none, \ 38℃ (0, 1, and 2 points, respectively); tenderness - none, mild, and severe (0, 1, and 2 points, respectively); goiter by ultrasonography or palpation - none and yes (0 and 1 point, respectively); and esr - normal, 25-60 mm/h, and \>60 mm/h (0, 1, and 2 points, respectively). exclusion criteria: * patients who were diagnosed with diabetes, an active peptic ulcer, benign and malignant tumors, hepatic dysfunction, recurrent sat, and already on glucocorticoid therapy were excluded within 3 months.

Keywords: short-term prednisone subacute thyroiditis open-label, randomized, controlled, and multicenter
the effect of tlr4 inhibition in obese and type 2 diabetic subjects

Conditions: Insulin Sensitivity

Summary: to determine whether pharmacologic inhibition of toll-like receptor 4 (tlr4) with eritoran for injection (e5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and t2dm) subjects.

e5564 = eritoran

Eligibility criteria:
inclusion criteria: * subjects capable of giving informed consent. * lean (bmi \<26 kg/m2) with normal glucose-tolerant subjects without a family history of type 2 dm * obese (bmi 30-37 kg/m2) with normal glucose-tolerant subjects * type 2 dm subjects base on ada criteria, who have hba1c \<8.5% and control with diet or sulfonylureas. * both genders. (50% males) * age = 18-65 years. older subjects are excluded because aging is a pro-inflammatory state. * all ethnic groups * premenopausal women in the follicular phase, non-lactating, and with a negative pregnancy test. postmenopausal women on stable dose of or not exposed to hormone replacement for \>=6 months. * lab: hematocrit \>=34%, serum creatinine \<=1.4 mg/dl, normal electrolytes, urinalysis, and coagulation tests. liver function tests up to 2x normal range. * stable body weight (+/-1%) for \>=3 months. * one or less sessions of strenuous exercise/wk for last 6 months. exclusion criteria: * current treatment with drugs known to affect glucose and lipid homeostasis. subjects on a stable dose of statin (\>3 months) are eligible. * non-steroidal anti-inflammatory drugs or systemic steroid use for more than 1 week within 3 months. * current treatment with anticoagulants (warfarin). aspirin (up to 325 mg) and clopidogrel will be permitted if these can be held for seven days prior to the biopsies. * history of heart disease (new york heart classification greater than class ii; more than non-specific st-t wave changes on the ecg), peripheral vascular disease, pulmonary disease, smokers. * poorly controlled blood pressure (systolic bp\>160, diastolic bp\>90 mmhg). * active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and psychiatric disease.

Keywords: insulin signaling and glucose disposal in muscle hepatic insulin sensitivity tlr4 signaling and inflammatory gene expression plasma cytokine concentration intramyocellular diacylglycerol and ceramide content
single-dose pharmacokinetics of oral nicotine replacement products

Conditions: Tobacco Dependence

Summary: this is an explorative study comparing new prototypes of nicotine replacement products with nicorette® gum.

this study included 40 subjects who were randomly assigned to one of eight treatment sequences. in four of the sequences, the three prototypes with the shorter dissolution time and the reference were used; in the remaining four sequences, the three prototypes with the longer dissolution time and the reference were used. hence, half of the subjects received the short prototypes and half received the long prototypes. subjects in both treatment groups (short and long) attended four treatment visits, each of 11 hours' duration, and periods of at least 36 hours' duration between treatment visits.

Eligibility criteria:
inclusion criteria: * healthy smokers, smoking at least 10 cigarettes daily during at least one year preceding inclusion and bmi between 17.5 and 30.0 kg/m2. * female participants of child-bearing potential are required to use a medically acceptable means of birth control. * a personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study. exclusion criteria: * pregnancy, lactation or intended pregnancy. * treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.

Keywords: smoking cessation nicotine pharmacokinetics
bone ultrasound to access fracture healing

Conditions: Forearm Fracture; Clavicle Fracture

Summary: the purpose of this study is to evaluate sequential fracture healing with radius/ulna fractures or clavicle fractures and compare ultrasound to radiographs.

investigators will recruit 60 pediatric and adult patients with complete radius, ulna and/or clavicle fractures and obtain ultrasound data from the fractured bones and the contralateral intact bone (as control) at each clinical visit. ultrasound will be compared to radiographs. completion of this aim will validate the concept and correlate clinical healing with ultrasound findings. for the ultrasound method, investigators will use ultrasound energy to produce a secondary mechanical vibration in bone that can be used to characterize the integrity of the bone. (this is in contrast with conventional sonography where ultrasound echoes are used to image the tissue.) the proposed method is based on the use of ultrasound radiation force (urf) to excite the bone. urf is a "pushing" force exerted by ultrasound on an object. this force can be static, transient (pulse), or harmonic. harmonic urf can be generated by modulating the amplitude of the ultrasound beam at a desired frequency. this force initiates bone vibration, where the frequency and amplitude of such vibrations depend on bone geometry and elastic properties. hence, any fracture (or fracture repair) will alter the vibration pattern, thus enabling us to monitor fracture and fracture healing by analyzing such patterns.

Eligibility criteria:
inclusion criteria: * forearm fractures and no patients with hemiplegia -or- * clavicle fractures exclusion criteria: * non-english speakers * known pregnancy
observational study of patients with duchenne muscular dystrophy theoretically treatable with exon 53 skipping

Conditions: Duchenne Muscular Dystrophy

Summary: preu7-53 is a natural history study. the objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with duchenne muscular dystrophy (dmd), potentially treatable with aav-mediated exon 53 skipping.


Eligibility criteria:
inclusion criteria: * diagnosis of duchenne muscular dystrophy confirmed by at least genetic testing, theoretically treatable by exon 53 skipping. * age between ≥ 12 and \<20 years old. * non ambulant patients (i;e; inability to walk more than 10 meters without any of assistance). * patients covered by a national health insurance scheme. * signed informed consent. exclusion criteria: * patient incapable of sitting upright in a wheelchair for at least one hour. * patients with severe intellectual impairment preventing them from fully understanding the exercises to be performed. * recent (less than 6 months ago) upper limb surgery or trauma this criteria is however no definitive. patients who have undergone upper limb surgery or trauma may nonetheless be enrolled once the 6 month period is over. * known immune deficiency. * contraindications to nmr exams

Keywords: duchenne muscular dystrophy strength and function tests mri
does maitake mushroom extract enhance hematopoiesis in myelodysplastic patients?

Conditions: Myelodysplastic Syndrome

Summary: researchers from memorial sloan-kettering cancer center, in collaboration with the new york presbyterian hospital-weill medical college of cornell university, are conducting a study of a medicinal mushroom extract called maitake (pronounced my-tock-e). laboratory studies show that maitake can reduce the growth of cancer in animals. the maitake does not kill cancer cells directly. it is believed to work through the immune system (the body's defense system against infection). our test tube, animal and human dose determining studies show that maitake can enhance immune function. we are conducting this study to see whether maitake improves the neutrophil count and function in patients with mds. the neutrophils are white blood cells which help to fight infection.


Eligibility criteria:
inclusion criteria: * mskcc patients age 18 or older able to sign informed consent * absolute neutrophil count \>0.5 k/mcl * diagnosis of mds by bone marrow biopsy * patient not a candidate for aggressive standard treatment exclusion criteria: * ipss (high risk) * history of aml * history of stem cell transplant * known history of hiv+ * allergy to mushrooms * bone marrow blasts \>10% healthy control eligibilty criteria inclusion criteria * age ≥55 years exclusion criteria * currently taking corticosteroids or other immunosuppressants * known history of hiv+ * current or previous malignancy or hematology disorder except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for \> 3 years

Keywords: mds maitake mushroom 09-094
evaluation of voice in behcet's

Conditions: Behcet Disease

Summary: behçet's disease (bd) is a systemic inflammatory condition of unknown origin with no definite aetiopathogenetic pathways accepted worldwide. to date, only a few studies have investigated laryngeal involvement in bd and data about this are scarce. for these reasons, the present study focuses on verifying the occurrence of vocal cord involvement in patients with bd, identifying potential correlations with specific demographic, clinical, and therapeutic characteristics.

behçet's disease (bd) is a systemic inflammatory condition of unknown origin with no definite aetiopathogenetic pathways accepted worldwide. bd owes its name to the turkish dermatologist hulusi behçet, whom published in 1937 two cases of oral aphthous, genital ulcers, and recurrent uveitis with hypopion, known as triple-symptom complex. in addition to these, other clinical features encompass musculoskeletal, gastrointestinal, renal, pulmonary, cardiovascular, and cutaneous manifestations including erythema nodosum and pseudofolliculitis.to date, only a few studies have investigated laryngeal involvement in bd and data about this are scarce. for these reasons, the present study focuses on verifying the occurrence of vocal cord involvement in patients with bd, identifying potential correlations with specific demographic, clinical, and therapeutic characteristics.the study will include 60 volunteers. they will divided into 2 groups. group i will comprise of the 30 patients with behçet's disease (bd), and group ii will comprise of 30 controls.the inclusion criteria for selection of group i participants will based on the criteria of the international study group which was proposed in 1990. the inclusion criteria for group ii will not have a behcet's disease.methods 1. history taking. 2. voice sample by recording (in sustained vowel \|a\| ) 3. auditory perceptual assessment (apa): (kotby et al., 1986) 4. laryngyscopic examination: patients will taken to a room with a tower on which the 8.5 mm 70 rigid laryngoscope (karl storz - endoscope) (tele pack x led). 5. acoustic analysis: the voice sample will be subjected to computerized acoustic analysis using multidimensional voice program software(mdvp).

Eligibility criteria:
inclusion criteria: * the inclusion criteria for selection of group i participants will based on the criteria of the international study group which was proposed in 1990. the inclusion criteria for group ii will not have a behcet's disease. exclusion criteria: * other autoimmune diseases.
autogenous demineralized dentin block graft versus autogenous bone block graft for alveolar ridge preservation

Conditions: Alveolar Bone Loss

Summary: the aim of this trial is to compare the effect of autogenous demineralized dentin block graft (addbg) versus autogenous bone block graft (abbg) harvested from maxillary tuberosity on alveolar ridge preservation after extraction of non-restorable single rooted teeth

many studies have reported an approximately 50% reduction in alveolar bone both the horizontal and vertical directions over 12 months with more than two-thirds of the reduction occurring in the first three months after extraction. alveolar ridge preservation is a procedure that attempts to reduce bone dimensional changes that naturally take place following tooth extraction. a broadly recognized approach is the maintenance of bone walls through bone substitute (graft) delivery into the socket, where guided bone regeneration may be a requisite. autogenous bone graft has osteogenic and osteoinductive effect. however, when attempts were made to use autologous bone chips in socket preservation, they failed to promote healing or stimulate hard tissue formation in the socket. on the other hand, autogenous bone block graft from the tuberosity has shown a feasible, user-friendly, low-cost solution for minimizing soft and hard tissue collapse and dimensional loss following single-rooted tooth extraction. moreover, root dentin block is composed of type i collagen matrix with several osteoinductive non-collagenous proteins such as bone morphogenetic proteins (bmp) and dentin matrix proteins. geometrically, alveolar bone morphology was maintained by dentin block graft as well as it has micropores (dentinal tubules) of 3-5 μm diameter and macropores of 0.2-0.3 mm diameter for enhancing osteoinductive and osteoconductive functions. both demineralized dentin block and autogenous bone block grafts has been utilized for alveolar ridge preservation or augmentation but the superiority of one form over the other is not yet clear

Eligibility criteria:
inclusion criteria: * non-restorable tooth indicated for extraction * single-rooted teeth * motivated patients, agree to sign informed consent and complete the follow-up period exclusion criteria: * pregnant females * active infection at extraction site * smokers * systemic conditions affecting healing (e.g. diabetes, medications as bisphosphonates...)
the effect of augmented reality based telerehabilitation application on neuromuscular and sensorimotor parameters in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: core stability, which is affected from the early period in with patients multiple sclerosis (pwms), is due to deterioration in the somatosensory, motor and musculoskeletal systems. based on the knowledge that core stability is effective on many functions, it is seen that trunk stabilization exercises are included in the physiotherapy and rehabilitation programs of patients. however, the effectiveness of augmented reality-based telerehabilitation application, which includes trunk stabilization training in pwms, has not been adequately investigated in the literature. the aim of the study is to investigate the effectiveness of augmented reality-based telerehabilitation application, which includes trunk stabilization training, on neuromuscular and sensorimotor parameters in pwms.


Eligibility criteria:
inclusion criteria: * diagnosed with relapsing remitting ms by a neurologist, * having a disability level between 1 and 5 according to the expanded disability status scale (edss), * those who get over 24 points in the standardized mini mental state test (smmt), * those who have not had an ms attack in the last three months, * volunteer individuals exclusion criteria: * receiving corticosteroid therapy in the last 4 weeks, * having additional neurological disease that may cause balance disorder * individuals who have had surgery related to the spine, hip, knee or ankle